Use of fingolimod in the treatment of periapical periodontitis

Abstract

The invention discloses the use of Fingolimod in treating periapical periodontitis. Through in vivo experiments, the present invention found that Fingolimod can significantly inhibit the infiltration of inflammatory cells and bone destruction in the local periapical lesions caused by pulp opening; and by reducing the expression levels of S1P1 and RANKL, it can dynamically adjust the ratio of RANKL / OPG in the local periapical inflammatory lesions, Achieve the effect of treating periapical periodontitis. The above results show that Fingolimod is an effective drug for treating apical periodontitis, and Fingolimod can be used to prepare a drug for treating apical periodontitis.

Description

technical field

[0001] The invention belongs to the technical field of prevention and treatment of apical periodontitis, and in particular relates to the use of Fingolimod in treating apical periodontitis. Background technique

[0002] Apical periodontitis is a common and frequently-occurring disease of the oral cavity. It usually develops from caries or pulp disease. The pathological features are mainly the destruction and absorption of periapical alveolar bone. Apical periodontitis is generally considered to be the result of mixed microbial infection in the root canal, so the main clinical treatment is to remove the infected substances through root canal treatment. However, according to previous X-ray surveys, 25% of the teeth after root canal treatment still have periapical bone destruction; through CT detection, it is found that about 63% of the teeth have periapical bone damage despite perfect root canal treatment. Peripheral bone defects still cannot heal, and eventua...

Examples

Embodiment 1

[0020] 1. Experimental animals and materials:

[0021] 1.1 Experimental animals

[0022] All experimental procedures complied with the guidelines of the Ethics Committee of the School of Stomatology, Wuhan University. Forty-eight female Wistar rats of SPF grade, weighing 200-220 grams, were purchased from the Experimental Animal Center of Hubei Province and raised in separate cages.

[0023] 1.2 Experimental materials

[0024] Fingolimod was purchased from LC laboratories in the United States. With reference to the drug instructions, it was prepared with normal saline to a drug working concentration of 0.4 mg / mL.

[0025] 2. Animal grouping and establishment of rat periapical periodontitis animal model:

[0026] 2.1 Animal grouping

[0027] They were randomly divided into 7-day model control group, 7-day Fingolimod administration group, 21-day model control group, 21-day Fingolimod administration group, 35-day model control group, and 35-day Fingolimod administration group...

technical field

[0001] The invention belongs to the technical field of prevention and treatment of apical periodontitis, and in particular relates to the use of Fingolimod in treating apical periodontitis. Background technique

[0002] Apical periodontitis is a common and frequently-occurring disease of the oral cavity. It usually develops from caries or pulp disease. The pathological features are mainly the destruction and absorption of periapical alveolar bone. Apical periodontitis is generally considered to be the result of mixed microbial infection in the root canal, so the main clinical treatment is to remove the infected substances through root canal treatment. However, according to previous X-ray surveys, 25% of the teeth after root canal treatment still have periapical bone destruction; through CT detection, it is found that about 63% of the teeth have periapical bone damage despite perfect root canal treatment. Peripheral bone defects still cannot heal, and eventua...

Examples

Embodiment 1

[0020] 1. Experimental animals and materials:

[0021] 1.1 Experimental animals

[0022] All experimental procedures complied with the guidelines of the Ethics Committee of the School of Stomatology, Wuhan University. Forty-eight female Wistar rats of SPF grade, weighing 200-220 grams, were purchased from the Experimental Animal Center of Hubei Province and raised in separate cages.

[0023] 1.2 Experimental materials

[0024] Fingolimod was purchased from LC laboratories in the United States. With reference to the drug instructions, it was prepared with normal saline to a drug working concentration of 0.4 mg / mL.

[0025] 2. Animal grouping and establishment of rat periapical periodontitis animal model:

[0026] 2.1 Animal grouping

[0027] They were randomly divided into 7-day model control group, 7-day Fingolimod administration group, 21-day model control group, 21-day Fingolimod administration group, 35-day model control group, and 35-day Fingolimod administration group...

Images